Failure to warn of Fosamax dangers prevents informed decisions
Merck, the manufacturer of Fosamax, continues to minimize the risk of osteonecrosis of the jaw associated with their medication. The failure to provide accurate information regarding this Fosamax danger has deprived women of the opportunity to weigh the risks against the benefits and make an informed decision.
>>INFORMATION: Fosamax side effects
As a side effect of Fosmax, many users have suffered jaw bone decay, known as osteonecrosis of the jaw (also known as ONJ). Typically the condition begins with pain or numbness in the jaw and sinuses. Osteonecrosis symptoms could include loosening of the teeth, lesions in the mouth and gum loss. As a result, surgery may be necessary to remove large portions of the decayed jawbone. This leads to an inability to chew solid foods, and a life-time liquid diet. If ONJ is left untreated, it can lead to septicemia and possibly death.
For each user, the decision whether to use a medication is a personal decision where the benefits must be weighed against the potential dangers. For many users, Fosamax provides minimal benefit because their level of bone loss has not reached the levels associated with osteoporosis or because they have limited risks of suffering serious injuries from fractures. Without the information that Fosamax dangers could lead to jaw decay, potential users have been deprived of necessary information to make an informed decision.
Our lawyers are pursuing Fosamax lawsuits as a result of this failure to warn. If you or a family member have suffered a jaw injury after taking Fosamax, request a consultation to determine if you may be eligible for a claim. Click here to request a free claim evaluation.
